Nikolai Naryshkin
Seminars
Thursday 12th November 2026
Roundtable Discussion: Characterizing Functionally Meaningful RNA– Protein Complexes to Enable Productive Drug Discovery
1:30 pm
- What is the minimal RNA–protein complex that recapitulates the functional event we intend to drug – for splicing, is that the initiation/commitment step?
- How should we distinguish binding that is merely observed from engagement of a functionally meaningful fraction of the target RNA population?
- What can structural biology of the functional complex reveal about ligand recognition and the determinants of modulation that structure of the isolated RNA cannot?
Thursday 12th November 2026
Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
3:30 pm
- Which disease areas beyond rare genetic indications – respiratory, immunology, and other high-prevalence settings – are genuinely within reach, and what makes a target there tractable?
- What new chemotypes, mechanisms, and platforms are needed to expand beyond risdiplam- and branaplam-like analogs and a handful of target classes – and how far should we extend the one validated mechanism class versus seek genuinely new ones?
- What translational, safety, and selectivity evidence is required to convince the field that RNA targeting is a generalizable modality rather than a niche?
